Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of M-Fluorophenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL3166960 | 0.89 | ALDH1A1 (0.54) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL7545682 | 0.87 | SLC7A5 (0.58) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3180965 | 0.87 | USP2 (0.49) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3176277 | 0.86 | ALDH1A1 (0.54) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3175839 | 0.86 | ALDH1A1 (0.46) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3160183 | 0.85 | ALDH1A1 (0.50) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3177641 | 0.84 | DPP7 (0.47) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3175208 | 0.83 | ALDH1A1 (0.52) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3159921 | 0.82 | ALDH1A1 (0.50) | ALDH1A1USP2LMNACYP1A2TSHR | |
| Gabapentin SCHEMBL3169781 | 0.81 | ALDH1A1 (0.50) | ALDH1A1USP2LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254344-A1 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | XENOPORT | 2004-12-16 | — | — | US | claimed |
| EP-1412324-A4 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | XENOPORT INC (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1412324-A2 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | Xenoport, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030181390-A1 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues | XENOPORT, INC. | 2003-09-25 | — | — | US | claimed |
| WO-2002100344-A2 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| US-7645797-B2 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues | XENOPORT, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080226716-A1 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATION OF GABA ANALOGUES | XENOPORT (US) | 2008-09-18 | — | — | US | disclosed |
| US-7420002-B2 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues | XENOPORT (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040254344-A1 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | XENOPORT | 2004-12-16 | — | — | US | disclosed |
| EP-1412324-A4 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | XENOPORT INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1412324-A2 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | Xenoport, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030181390-A1 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues | XENOPORT, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2002100344-A2 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254344-A1 | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | SLC6A1, SLC6A13, SLC6A11 | CACNA2D1 1384/4885ALDH1A1 241/4885USP2 1110/4885 |
| US-20080226716-A1 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATION OF GABA ANALOGUES | SLC6A13, SLC6A1, SLC6A11 | CACNA2D1 1285/4885ALDH1A1 545/4885USP2 1502/4885 |
| US-20030181390-A1 | Amino acid conjugates providing for sustained systemic concentrations of GABA analogues | SLC6A1, SLC6A13, SLC6A11 | CACNA2D1 1615/4885ALDH1A1 426/4885USP2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.